Evonetix is a pioneering biotech company based in Cambridge, focused on revolutionizing the field of synthetic biology through its innovative DNA synthesis platform. The company serves researchers and institutions in the biotechnology and life sciences sectors, providing them with a highly parallel desktop platform that enables the synthesis of DNA with unprecedented accuracy, scale, and speed. Operating in the rapidly growing synthetic biology market, Evonetix's business model revolves around the commercialization of its proprietary technology, which facilitates the creation and manipulation of genetic material. This platform democratizes access to DNA synthesis, allowing researchers to conduct experiments and develop applications more efficiently and cost-effectively. Evonetix generates revenue through the sale of its DNA synthesis platform and related services, targeting a broad range of clients from academic institutions to commercial biotech firms. The company's innovative approach has earned it recognition, including being named Biotech Scale up of the Year at the 2020 Business Weekly Awards.

Keywords: DNA synthesis, synthetic biology, biotech, desktop platform, gene synthesis, biotechnology, life sciences, innovation, Cambridge, research tools.